X5050 is a REST inhibitor, with an EC 50 of 2.1 μM.

X5050 (100 μM, 1 day) induces a dosedependent decrease in the REST isoform in protein level[1]. Western Blot Analysis[1]Cell Line: NSCs. Concentration: 100 μM. Incubation Time: One day. Result: Induced a dosedependent decrease in the 122 kDa longer REST isoform.

X5050 (2 x 2μl of 20 mM) is active in HD pathological context[1]. Animal Model: 12-week-old male C57Bl6 mice[1].2 Dosage: 2 x 2μl of 20 mM in 10% DMSO in water. Administration: Intraventricular injection. Result: Increased BDNF expression. A decrease in Darpp32 and Snap25 expression was found by QRT-PCR in the lesioned striatum as compared with the contralateral striatum. Significantly increased the levels of Bdnf II splice variant (exon II containing variant) while Bdnf IV levels were not significantly changed.